[go: up one dir, main page]

MX2018004518A - Composiciones y metodos para reducir la formacion de cristales de hielo. - Google Patents

Composiciones y metodos para reducir la formacion de cristales de hielo.

Info

Publication number
MX2018004518A
MX2018004518A MX2018004518A MX2018004518A MX2018004518A MX 2018004518 A MX2018004518 A MX 2018004518A MX 2018004518 A MX2018004518 A MX 2018004518A MX 2018004518 A MX2018004518 A MX 2018004518A MX 2018004518 A MX2018004518 A MX 2018004518A
Authority
MX
Mexico
Prior art keywords
peptoid
methods
compositions
polymers
crystal formation
Prior art date
Application number
MX2018004518A
Other languages
English (en)
Other versions
MX391259B (es
Inventor
Wei Xiaoxi
Original Assignee
X Therma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by X Therma Inc filed Critical X Therma Inc
Publication of MX2018004518A publication Critical patent/MX2018004518A/es
Publication of MX391259B publication Critical patent/MX391259B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10Preservation of living parts
    • A01N1/12Chemical aspects of preservation
    • A01N1/122Preservation or perfusion media
    • A01N1/125Freeze protecting agents, e.g. cryoprotectants or osmolarity regulators
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23BPRESERVATION OF FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES; CHEMICAL RIPENING OF FRUIT OR VEGETABLES
    • A23B2/00Preservation of foods or foodstuffs, in general
    • A23B2/70Preservation of foods or foodstuffs, in general by treatment with chemicals
    • A23B2/725Preservation of foods or foodstuffs, in general by treatment with chemicals in the form of liquids or solids
    • A23B2/729Organic compounds; Microorganisms; Enzymes
    • A23B2/762Organic compounds containing nitrogen
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23BPRESERVATION OF FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES; CHEMICAL RIPENING OF FRUIT OR VEGETABLES
    • A23B2/00Preservation of foods or foodstuffs, in general
    • A23B2/80Freezing; Subsequent thawing; Cooling
    • A23B2/85Freezing; Subsequent thawing; Cooling with addition of or treatment with chemicals
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23BPRESERVATION OF FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES; CHEMICAL RIPENING OF FRUIT OR VEGETABLES
    • A23B4/00Preservation of meat, sausages, fish or fish products
    • A23B4/14Preserving with chemicals not covered by groups A23B4/02 or A23B4/12
    • A23B4/18Preserving with chemicals not covered by groups A23B4/02 or A23B4/12 in the form of liquids or solids
    • A23B4/20Organic compounds; Microorganisms; Enzymes
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23GCOCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G9/00Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor
    • A23G9/32Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor characterised by the composition containing organic or inorganic compounds
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23GCOCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G9/00Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor
    • A23G9/32Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor characterised by the composition containing organic or inorganic compounds
    • A23G9/38Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor characterised by the composition containing organic or inorganic compounds containing peptides or proteins
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L13/00Meat products; Meat meal; Preparation or treatment thereof
    • A23L13/40Meat products; Meat meal; Preparation or treatment thereof containing additives
    • A23L13/42Additives other than enzymes or microorganisms in meat products or meat meals
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L17/00Food-from-the-sea products; Fish products; Fish meal; Fish-egg substitutes; Preparation or treatment thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64Proteins; Peptides; Derivatives or degradation products thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/84Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
    • A61K8/88Polyamides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q90/00Cosmetics or similar toiletry preparations for specific uses not provided for in other groups of this subclass
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/02Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids
    • C08G69/08Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids derived from amino-carboxylic acids
    • C08G69/10Alpha-amino-carboxylic acids
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08KUse of inorganic or non-macromolecular organic substances as compounding ingredients
    • C08K5/00Use of organic ingredients
    • C08K5/16Nitrogen-containing compounds
    • C08K5/20Carboxylic acid amides
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08LCOMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L77/00Compositions of polyamides obtained by reactions forming a carboxylic amide link in the main chain; Compositions of derivatives of such polymers
    • C08L77/04Polyamides derived from alpha-amino carboxylic acids
    • CCHEMISTRY; METALLURGY
    • C09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09KMATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K3/00Materials not provided for elsewhere
    • C09K3/18Materials not provided for elsewhere for application to surfaces to minimize adherence of ice, mist or water thereto; Thawing or antifreeze materials for application to surfaces
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/54Polymers characterized by specific structures/properties

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • General Health & Medical Sciences (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Dentistry (AREA)
  • Environmental Sciences (AREA)
  • Combustion & Propulsion (AREA)
  • Materials Engineering (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Cosmetics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Storage Of Fruits Or Vegetables (AREA)
  • Medicinal Preparation (AREA)
  • Dairy Products (AREA)
  • Confectionery (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

La presente invención proporciona polímeros peptoides capaces de reducir o inhibir la formación de cristales de hielo a temperaturas por debajo de 0°C. También se proporcionan híbridos peptoide-péptido que comprenden los polímeros peptoides proporcionados en este documento. Los polímeros peptoides y los híbridos peptoide-péptido proporcionados en la presente son útiles para preparar soluciones crioprotectoras. Los polímeros peptoides, híbridos peptoide-péptido y las soluciones crioprotectoras proporcionadas en la presente son útiles para preparar soluciones anticongelantes, productos alimenticios congelados y productos para el cuidado cosmético. También se proporcionan en la presente métodos para conservar un tejido, un órgano, una célula o una macromolécula biológica usando las composiciones descritas en este documento.
MX2018004518A 2015-10-14 2016-10-13 Composiciones y métodos para reducir la formación de cristales de hielo. MX391259B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562241588P 2015-10-14 2015-10-14
PCT/US2016/056852 WO2017066454A2 (en) 2015-10-14 2016-10-13 Compositions and methods for reducing ice crystal formation

Publications (2)

Publication Number Publication Date
MX2018004518A true MX2018004518A (es) 2018-09-18
MX391259B MX391259B (es) 2025-03-21

Family

ID=58518569

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018004518A MX391259B (es) 2015-10-14 2016-10-13 Composiciones y métodos para reducir la formación de cristales de hielo.

Country Status (12)

Country Link
US (5) US9986733B2 (es)
EP (1) EP3370518B1 (es)
JP (2) JP7011830B2 (es)
KR (1) KR102686073B1 (es)
CN (1) CN108347916B (es)
AU (1) AU2016338410B2 (es)
CA (1) CA3001065A1 (es)
ES (1) ES2958531T3 (es)
IL (1) IL258648A (es)
MX (1) MX391259B (es)
SG (1) SG11201802777XA (es)
WO (1) WO2017066454A2 (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12010987B2 (en) 2004-10-07 2024-06-18 Transmedics, Inc. Systems and methods for ex-vivo organ care and for using lactate as an indication of donor organ status
US9814230B2 (en) 2008-01-31 2017-11-14 Transmedics, Inc. Systems and methods for ex vivo lung care
MX391259B (es) 2015-10-14 2025-03-21 X Therma Inc Composiciones y métodos para reducir la formación de cristales de hielo.
US11110176B2 (en) 2016-11-25 2021-09-07 The Board Of Trustees Of The California State University Composition and method for the protection of proteins, cell components and cells during temperature stress
WO2018191371A1 (en) * 2017-04-12 2018-10-18 X-Therma, Inc. Novel supercooling methods for preservation of biological samples
EP3609906B1 (en) * 2017-04-12 2024-03-20 X-Therma, Inc. Novel peptoid polymers and methods of use
GB201708999D0 (en) 2017-06-06 2017-07-19 Univ Warwick Recrystallization Inhibitor
FR3072246B1 (fr) * 2017-10-13 2020-06-12 Biodesiv Efnium Polymere antimicrobien pour semences animales
WO2019099922A1 (en) * 2017-11-16 2019-05-23 X-Therma, Inc. Cavity-containing oligomers and polymers effective in cryopreservation
CN108359613B (zh) * 2018-05-14 2022-04-29 安发(福建)生物科技有限公司 冬虫夏草菌抗冻剂及基于该抗冻剂的超低温保藏和复苏方法
CN108795392B (zh) * 2018-06-25 2020-10-02 浙江工业大学 一种用于食品保鲜的不冻液
CN108910010A (zh) * 2018-06-25 2018-11-30 浙江工业大学 一种海上绿色安全保藏水产品的方法
TWI837281B (zh) * 2019-01-17 2024-04-01 日商長瀨產業股份有限公司 細胞冷凍保存液及細胞的漸凍方法
AR118008A1 (es) 2019-02-07 2021-09-08 Vitricell Sa Composiciones para criopreservación de un material biológico
JP7350505B2 (ja) * 2019-02-15 2023-09-26 イビデン株式会社 生体試料を含む固化体
US12453345B2 (en) * 2019-04-09 2025-10-28 Institute Of Chemistry, Chinese Academic Of Sciences Serum-free cryopreservation solution and preparation method and application thereof
WO2020207150A1 (zh) * 2019-04-09 2020-10-15 中国科学院化学研究所 一种仿生控冰材料及含有该仿生控冰材料的冷冻保存液
JP7459130B2 (ja) * 2019-04-09 2024-04-01 北京大学第三医院(北京大学第三臨床医学院) 融解液及びその調製方法並びに応用
WO2020207151A1 (zh) * 2019-04-09 2020-10-15 北京大学第三医院(北京大学第三临床医学院) 一种无dmso的冷冻保存液及其制备方法与应用
CN111789102B (zh) * 2019-04-09 2022-07-12 北京大学第三医院 一种解冻液在冷冻保存的卵母细胞或胚胎解冻中的应用
CN111789099B (zh) * 2019-04-09 2022-09-06 北京大学第三医院 一种含肽类化合物的冷冻保存液在卵母细胞或胚胎冻存中的应用
CN110231821B (zh) * 2019-06-03 2022-05-31 哈尔滨工程大学 多机器人编队的改进自适应零空间行为融合方法
CN110408052B (zh) * 2019-07-09 2022-03-25 长春工业大学 一种鱼抗冻蛋白仿生的耐冻粘韧水凝胶及其制备方法
CN110800733A (zh) * 2019-11-21 2020-02-18 武汉光谷中源协和细胞基因科技有限公司 一种脐带间充质干细胞用冻存液及试剂盒
EP3831203A1 (en) 2019-12-03 2021-06-09 Seoul National University R & DB Foundation Composition for inhibiting ice recrystallization
KR102368783B1 (ko) 2019-12-03 2022-03-02 서울대학교산학협력단 얼음 결정의 형성 또는 성장 억제용 조성물
KR102274195B1 (ko) * 2019-12-04 2021-07-08 고려대학교 산학협력단 자기 조립 화합물을 포함하는 항-동결 조성물
US20210267224A1 (en) * 2020-02-27 2021-09-02 Independent Quality Foods, Llc Composition and process for long term preservation of food
CN113383766A (zh) * 2020-03-12 2021-09-14 中国科学院化学研究所 一种用于干细胞冷冻保存的冻存液及其制备方法
CN111345282A (zh) * 2020-03-17 2020-06-30 广东万海细胞生物科技有限公司 一种细胞冻存液及冻存方法
CN111802440A (zh) * 2020-07-17 2020-10-23 青岛贵仕生物科技有限公司 一种冻干海鱼食物的保鲜储藏方法
CN112056386B (zh) * 2020-09-03 2022-10-28 余姚谷满仓食品有限公司 一种速冻绿花菜的加工工艺
CN112400863A (zh) * 2020-11-26 2021-02-26 成都康景生物科技有限公司 一种临床用nk细胞冻存液及冻存方法
KR102454226B1 (ko) * 2020-12-04 2022-10-14 고려대학교 산학협력단 Dna 나노구조체를 포함하는 동결 보호용 조성물 및 그 이용방법
EP4197988A1 (en) * 2021-12-17 2023-06-21 Raytheon Technologies Corporation Freeze drying of composites for filament spreading
CN121078978A (zh) * 2022-07-18 2025-12-05 21 世纪医药公司 用于超快速制备角膜以进行玻璃化的方法和设备
CN116138247A (zh) * 2023-01-31 2023-05-23 清华大学 一种动物组织冷冻保护用组合试剂及其应用和方法
CN116491500A (zh) * 2023-05-09 2023-07-28 博生吉安科细胞技术有限公司 一种nk细胞冻存液及其制备方法与应用
CN119661834A (zh) * 2024-11-12 2025-03-21 江苏大学 一种具有抗冻活性的四链星形聚类肽及其制备方法和应用

Family Cites Families (211)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4672037A (en) * 1983-11-03 1987-06-09 American Type Culture Collection Method of culturing freeze-dried microorganisms
US5071741A (en) * 1988-04-18 1991-12-10 Cryolife, Inc. Cryoprotective agent and its use in cryopreservation of cellular matter
US5223015A (en) * 1988-07-07 1993-06-29 Shin Charles C H Cryoprotectant composition
US5811387A (en) 1990-05-15 1998-09-22 Chiron Corporation Peptoid mixtures
US20030105286A1 (en) 1991-05-24 2003-06-05 Michael Egholm Linked peptide nucleic acids
US5641625A (en) 1992-05-22 1997-06-24 Isis Pharmaceuticals, Inc. Cleaving double-stranded DNA with peptide nucleic acids
US7223833B1 (en) 1991-05-24 2007-05-29 Isis Pharmaceuticals, Inc. Peptide nucleic acid conjugates
DK51092D0 (da) 1991-05-24 1992-04-15 Ole Buchardt Oligonucleotid-analoge betegnet pna, monomere synthoner og fremgangsmaade til fremstilling deraf samt anvendelser deraf
US6451968B1 (en) 1991-05-24 2002-09-17 Isis Pharmaceuticals, Inc. Peptide nucleic acids
US6228982B1 (en) 1992-05-22 2001-05-08 Benget Norden Double-stranded peptide nucleic acids
US6713602B1 (en) 1991-05-24 2004-03-30 Ole Buchardt Synthetic procedures for peptide nucleic acids
US5539082A (en) 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
US6441130B1 (en) 1991-05-24 2002-08-27 Isis Pharmaceuticals, Inc. Linked peptide nucleic acids
US5714331A (en) 1991-05-24 1998-02-03 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
US6414112B1 (en) 1991-05-24 2002-07-02 Ole Buchardt Peptide nucleic acids having 2,6-diaminopurine nucleobases
US5719262A (en) 1993-11-22 1998-02-17 Buchardt, Deceased; Ole Peptide nucleic acids having amino acid side chains
US5766855A (en) 1991-05-24 1998-06-16 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity and sequence specificity
US20030232355A1 (en) 1992-05-22 2003-12-18 Isis Pharmaceuticals, Inc. Double-stranded peptide nucleic acids
US6770738B1 (en) 1992-05-22 2004-08-03 Isis Pharmaceuticals, Inc. Higher order structure and binding of peptide nucleic acids
DE69332524T2 (de) 1992-09-24 2003-04-24 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Synthese von N-substituierten Oligomeren
US5877278A (en) 1992-09-24 1999-03-02 Chiron Corporation Synthesis of N-substituted oligomers
US5831005A (en) 1992-09-24 1998-11-03 Chiron Corporation Synthesis of N-substituted oligomers
EP0618191A1 (en) 1993-04-02 1994-10-05 AMERSHAM INTERNATIONAL plc Metal chelating compounds
US6350853B1 (en) 1993-04-26 2002-02-26 Peter E. Nielsen Conjugated peptide nucleic acids having enhanced cellular uptake
US7825215B1 (en) 1993-04-26 2010-11-02 Peter E. Nielsen Substituted nucleic acid mimics
US5840485A (en) 1993-05-27 1998-11-24 Selectide Corporation Topologically segregated, encoded solid phase libraries
CA2163637C (en) 1993-05-27 2008-05-06 Michal Lebl Topologically segregated, encoded solid phase libraries
US5608110A (en) 1993-06-15 1997-03-04 Bracco International B.V. Heteroatom-bearing ligands and metal complexes thereof
ES2159303T3 (es) 1993-09-30 2001-10-01 Nippon Steel Corp Peptidos activos como inhibidores de la agregacion de plaquetas.
US6710164B1 (en) 1993-11-22 2004-03-23 Peter E. Nielsen Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
AT401930B (de) 1993-12-27 1996-12-27 Chemie Linz Gmbh Verfahren zur herstellung von n-substituierten glycinestern und verfahren zur indigosynthese aus den so hergestellten glycinestern
ATE280777T1 (de) 1994-03-09 2004-11-15 Cortech Inc Bradykinin-antagonist peptide mit n- substituierten glycinen
US5696231A (en) 1994-12-21 1997-12-09 Corvas International, Inc. N-substituted glycine derivatives as enzyme inhibitors
US6025472A (en) 1994-12-21 2000-02-15 Corvas International, Inc. N-substituted glycine derivatives as enzyme inhibitors
US5481020A (en) 1994-12-30 1996-01-02 Chiron Corporation Opiate receptor ligands
US6169073B1 (en) 1995-02-16 2001-01-02 Bayer Corporation Peptides and peptidomimetics with structural similarity to human p53 that activate p53 function
GB9508195D0 (en) 1995-04-20 1995-06-07 Univ British Columbia Novel biologically active compounds and compositions,their use and derivation
US6248713B1 (en) 1995-07-11 2001-06-19 Biogen, Inc. Cell adhesion inhibitors
DE19538246C2 (de) * 1995-10-13 1999-01-21 Bayer Ag Ein Kühlmedium für den Einsatz bei erhöhten Betriebstemperaturen
US6096710A (en) 1995-11-17 2000-08-01 The Regents Of The University Of California Collagen-like peptoid residue-containing structures
US6239108B1 (en) 1996-07-11 2001-05-29 Biogen, Inc. Cell adhesion inhibitors
CA2262647C (en) 1996-08-08 2007-12-04 Amylin Pharmaceuticals, Inc. Methods for regulating gastrointestinal motility
ATE252914T1 (de) 1996-08-13 2003-11-15 Chiron Corp Zusammensetzungen zur polynukleotidabgabe
PT1629849E (pt) 1997-01-07 2013-07-09 Amylin Pharmaceuticals Llc Composições farmacêuticas que compreendem exendinas e seus agonistas
US6841657B2 (en) 1997-04-17 2005-01-11 Whitehead Institute For Biomedical Research Inhibitors of HIV membrane fusion
JP4727769B2 (ja) 1997-04-28 2011-07-20 ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド 試薬再循環を用いてオリゴマー、特に、ペプトイドを合成するための装置
ES2210761T3 (es) 1997-05-21 2004-07-01 The Board Of Trustees Of The Leland Stanford Junior University Composicion y procedimiento para mejorar el transporte a traves de las membranas biologicas.
US6107470A (en) 1997-05-29 2000-08-22 Nielsen; Peter E. Histidine-containing peptide nucleic acids
US5989925A (en) 1997-06-27 1999-11-23 Serex, Inc. Antibody to and assay for peptide linked-pyridinoline as indicator of bone resorption level
FR2766179B1 (fr) 1997-07-16 2000-03-17 Oreal Nouvelles bases d'oxydation cationiques, leur utilisation pour la teinture d'oxydation des fibres keratiniques, compositions tinctoriales et procedes de teinture
US7157555B1 (en) 1997-08-08 2007-01-02 Amylin Pharmaceuticals, Inc. Exendin agonist compounds
TW460478B (en) 1997-08-15 2001-10-21 Chugai Pharmaceutical Co Ltd Phenethylamine derivatives
US7220721B1 (en) 1997-11-14 2007-05-22 Amylin Pharmaceuticals, Inc. Exendin agonist peptides
WO1999025727A2 (en) 1997-11-14 1999-05-27 Amylin Pharmaceuticals, Inc. Novel exendin agonist compounds
US6001815A (en) 1997-12-25 1999-12-14 Nisshin Flour Milling Co., Ltd. Depsipeptides containing N-substituted glycine residue
US6232494B1 (en) 1998-02-12 2001-05-15 Monsanto Company Process for the preparation of N-(phosphonomethyl)glycine by oxidizing N-substituted N-(phosphonomethyl)glycine
US6703359B1 (en) 1998-02-13 2004-03-09 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and GLP-1
US6238637B1 (en) 1998-02-26 2001-05-29 Monsanto Company Process and apparatus for preparation of phosphorus oxyacids from elemental phosphorus
US6468977B1 (en) 1998-03-02 2002-10-22 Apotex Inc. Thiadiazole compounds useful as inhibitors of cysteine activity dependent enzymes
US20010039020A1 (en) 1998-05-08 2001-11-08 Ronald Zuckermann Method and device for nonsynthetic deconvolution
JP4522587B2 (ja) 1998-12-01 2010-08-11 ファイロニックス ファーマシューティカルズ, インコーポレイテッド 異種細胞を魚に導入するための方法
US6458766B1 (en) 1998-12-15 2002-10-01 The Regents Of The University Of California Halovir, an antiviral marine natural product, and derivatives thereof
US7399489B2 (en) 1999-01-14 2008-07-15 Amylin Pharmaceuticals, Inc. Exendin analog formulations
US6924264B1 (en) 1999-04-30 2005-08-02 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
US6506724B1 (en) 1999-06-01 2003-01-14 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
EP1064938A1 (en) 1999-06-28 2001-01-03 Sanofi-Synthelabo Pharmaceutical dosage forms for controlled release producing at least a timed pulse
US20040258750A1 (en) 1999-06-28 2004-12-23 Gerard Alaux Timed dual release dosage forms comprising a short acting hypnotic or a salt thereof
WO2001002363A2 (en) 1999-07-06 2001-01-11 Vertex Pharmaceuticals Incorporated N-substituted glycine derivatives
US6677445B1 (en) 1999-08-27 2004-01-13 Chiron Corporation Chimeric antisense oligonucleotides and cell transfecting formulations thereof
US6783929B1 (en) 1999-11-02 2004-08-31 Chiron Corporation Biological sample component purification and differential display
US6306204B1 (en) 1999-11-24 2001-10-23 Xerox Corporation Ink jet ink compositions and printing processes
US6887845B2 (en) 2000-02-16 2005-05-03 Northwestern University Polypeptoid pulmonary surfactants
US6376708B1 (en) 2000-04-11 2002-04-23 Monsanto Technology Llc Process and catalyst for dehydrogenating primary alcohols to make carboxylic acid salts
US20040241176A1 (en) * 2000-04-27 2004-12-02 Ap Cells. Inc. Method of producing membrane vesicles
US6812237B2 (en) 2000-05-15 2004-11-02 Novartis Ag N-substituted peptidyl nitriles as cysteine cathepsin inhibitors
ATE360207T1 (de) 2000-06-05 2007-05-15 Novartis Vaccines & Diagnostic Mikroarrays für durchführen von proteomanalyse
US7153682B2 (en) 2000-06-05 2006-12-26 Chiron Corporation Microarrays on mirrored substrates for performing proteomic analyses
US7148058B2 (en) 2000-06-05 2006-12-12 Chiron Corporation Protein microarrays on mirrored surfaces for performing proteomic analyses
AU2001273189A1 (en) 2000-07-06 2002-01-21 Pharmacia Corporation Process for the preparation of derivatives of 4-amino-3-hydroxypyrrole-2-carboxylic acid
US6811977B2 (en) 2000-07-27 2004-11-02 California Institute Of Technology Rapid, quantitative method for the mass spectrometric analysis of nucleic acids for gene expression and genotyping
US6608026B1 (en) 2000-08-23 2003-08-19 Board Of Regents, The University Of Texas System Apoptotic compounds
ES2169690B1 (es) 2000-10-06 2004-03-16 Diverdrugs Sl Trimeros de n-alquilglicina capaces de proteger a neuronas contra agresiones excitotoxicas, y composiciones que los contienen.
ES2169691B1 (es) 2000-10-11 2004-03-16 Diverdrugs Sl Trimeros de n-alquilglicina capaces de bloquear la respuesta a sustancias quimicas, estimulos termicos o mediadores de la inflamacion de receptores neuronales, y composiciones que los contienen.
EP1404867B1 (en) 2000-12-23 2008-02-27 Novartis Vaccines and Diagnostics, Inc. Oligonucleotide transfection screening method
AU2002240201A1 (en) 2001-02-02 2002-08-19 Yale University Peptides for facilitating composite receptor expression and translocation of macromolecules
AU2002303259A1 (en) 2001-04-06 2002-10-21 Chiron Corporation Peptides incorporating chemoselective functionalities
US7163934B2 (en) 2001-05-04 2007-01-16 Corcept Therapeutics, Inc. Methods for treating delirium glucocorticoid receptor-specific antagonists
CA2463776A1 (en) 2001-10-18 2003-04-24 Monsanto Technology Llc Process and catalyst for dehydrogenating primary alcohols to make carboxylic acid salts
US7026166B2 (en) 2002-01-22 2006-04-11 Chiron Corporation Fluorogenic dyes
US20030235852A1 (en) 2002-04-19 2003-12-25 Roberts Richard W. Nucleic acid-peptide display libraries containing peptides with unnatural amino acid residues, and methods of making same using peptide modifying agents
US7019094B2 (en) 2002-05-31 2006-03-28 Biotage Ab Intermediate products, methods for their preparation and use thereof
US7736909B2 (en) 2003-01-09 2010-06-15 Board Of Regents, The University Of Texas System Methods and compositions comprising capture agents
US7704756B2 (en) 2003-01-21 2010-04-27 Novartis Vaccines And Diagnostics, Inc. Fluorogenic dyes
WO2004080444A2 (en) 2003-03-10 2004-09-23 Dynogen Pharmaceuticals, Inc. Methods for treating lower urinary tract disorders and the related disorders vulvodynia and vulvar vestibulitis using cav2.2 subunit calcium channel modulators
US20040192564A1 (en) 2003-03-25 2004-09-30 Vasudevan Balasubramaniam Bimodal gear lubricant formulation
CA2522203A1 (en) 2003-04-15 2004-10-28 Gema Tarrason Identification of n-alkylglycine trimers for induction of apoptosis
AU2003232253A1 (en) 2003-05-02 2004-11-23 Polyphor Ag Template-fixed beta-hairpin peptidomimetics with cxcr4 antagonizing activity
DE10320453A1 (de) 2003-05-08 2004-11-25 Morphochem AG Aktiengesellschaft für kombinatorische Chemie Neue Bioisostere von Actinonin
WO2004110774A1 (en) 2003-06-18 2004-12-23 Fuji Photo Film B.V. Ink-jet recording medium
EP1995256A1 (en) 2003-07-30 2008-11-26 University of Pittsburgh of the Commonwealth System of Higher Education EPHA2 T-cell epitope agonists and uses therefor
US20060035242A1 (en) 2004-08-13 2006-02-16 Michelitsch Melissa D Prion-specific peptide reagents
JP4709149B2 (ja) 2003-08-13 2011-06-22 ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド プリオン特異的ペプチド試薬
TW200526677A (en) 2003-08-22 2005-08-16 Monsanto Technology Llc Process for the preparation of N-phosphonomethylglycine and derivatives thereof
WO2005027633A2 (en) * 2003-09-16 2005-03-31 21St Century Medicine, Inc. Methods and compositions for the cryopreservation of organs
DE602004007677T2 (de) 2003-10-03 2008-04-17 Fujifilm Manufacturing Europe B.V. Tintenstrahl-aufzeichnungsmedium
CN1906308B (zh) 2003-12-19 2011-09-14 诺华疫苗和诊断公司 小干扰rna的细胞转染制剂、相关组合物以及制备和使用方法
US7576175B2 (en) 2004-05-27 2009-08-18 The Regents Of The University Of California Alpha-4 beta-1 integrin ligands for imaging and therapy
US7740861B2 (en) 2004-06-16 2010-06-22 University Of Massachusetts Drug delivery product and methods
EP1771162B1 (en) 2004-07-19 2013-06-05 Xenia Pharma Capsaicin inhibitors for the treatment of obesity-related disorders
US20060142319A1 (en) 2004-12-14 2006-06-29 Bang-Chi Chen Pyridyl-substituted spiro-hydantoin crystalline forms and process
US20090011946A1 (en) 2004-12-20 2009-01-08 Kalinex Use of Sequence Specific Polymers in Chemical Detection
MX2007008497A (es) 2005-01-13 2007-09-14 Novartis Vaccines & Diagnostic Ensayos inmunosorbentes enlazados a enzimas usando reactivos de peptidos especificos de prion.
WO2006110887A2 (en) 2005-04-11 2006-10-19 Amylin Pharmaceuticals, Inc Use of glp-1, exendin and agonists thereof to delay or prevent cardiac remodeling
GB0507537D0 (en) 2005-04-14 2005-05-18 Univ Durham Protein resistant surfaces
DE102005024017A1 (de) 2005-05-25 2006-11-30 Merck Patent Gmbh Chinazolinone
AU2006278264B2 (en) * 2005-08-05 2012-12-06 Araim Pharmaceuticals, Inc. Tissue protective peptides and uses thereof
US20070054298A1 (en) 2005-08-12 2007-03-08 Kent Kirshenbaum Methods for enzyme-mediated coupling of oligomers
US20070042041A1 (en) 2005-08-17 2007-02-22 Board Of Trustees Of The University Of Arkansas Drug-surfactant complexes for sustained release
BRPI0615618A2 (pt) 2005-09-09 2011-05-24 Novartis Ag reagentes peptóides especìficos para prìon
WO2007070509A2 (en) 2005-12-13 2007-06-21 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Epithelial sodium channel inhibiting agents and uses therefor
UA95788C2 (en) 2005-12-15 2011-09-12 Ф. Хоффманн-Ля Рош Аг Fused pyrrole derivatives
DK1976828T3 (en) 2005-12-29 2017-03-06 Celtaxsys Inc DIAMINE DERIVATIVES AS INhibitors of Leukotriene A4 HYDROLASE
WO2007079003A2 (en) 2005-12-29 2007-07-12 Bayer Schering Pharma Aktiengesellschaft Amide inhibitors of leukotriene a4 hydrolase
WO2007076555A2 (en) 2005-12-29 2007-07-05 Aechelon Technology, Inc. A location based wireless collaborative environment with a visual user interface
US8524663B2 (en) 2006-03-03 2013-09-03 New York University Method for site-specific polyvalent display on polymers
AR059733A1 (es) 2006-03-07 2008-04-23 Smithkline Beecham Corp Compuesto derivado de glicina n- sustituida con heteroaromaticos bicicicos, composicion farmaceutica que lo comprende, uso para preparar un medicamento para tratar la anemia y proceso para su preparacion
WO2007136990A2 (en) 2006-05-16 2007-11-29 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
TWI394747B (zh) 2006-06-23 2013-05-01 Smithkline Beecham Corp 脯胺醯基羥化酶抑制劑
DE102006039615A1 (de) 2006-08-24 2008-03-13 Leibniz-Institut Für Pflanzenbiochemie Esterelongationsverfahren zum sequenzgesteuerten Aufbau alternierender Peptid-Peptoid-Polymere (Peptid-Peptoid-Polymere)
KR100905901B1 (ko) 2006-09-07 2009-07-02 웅진코웨이주식회사 폴리아미드 역삼투 복합막 활성층 형성용 아민 수용액,이를 이용한 폴리아미드 역삼투 복합막, 및 이의 제조방법
US8486370B2 (en) 2006-09-08 2013-07-16 The Regents Of The University Of California Heterocyclic ligands for integrin imaging and therapy
US20090239273A1 (en) 2006-09-29 2009-09-24 Hisashi Semba Novel high-activity modified s-hydroxynitrile lyase
CA2668500C (en) 2006-11-08 2018-07-31 Chongxi Yu Transdermal delivery systems of peptides and related compounds
TW200845994A (en) 2007-01-12 2008-12-01 Smithkline Beecham Corp N-substituted glycine derivatives: prolyl hydroxylase inhibitors
TW200845991A (en) 2007-01-12 2008-12-01 Smithkline Beecham Corp N-substituted glycine derivatives: hydroxylase inhibitors
WO2008118848A1 (en) 2007-03-23 2008-10-02 Trustees Of Tufts College N-substituted peptidomimetic inhibitors of dipeptidylpeptidase iv
KR100805208B1 (ko) 2007-03-27 2008-02-21 주식회사 펩트론 엑센딘 함유 서방성 제제 조성물, 엑센딘 함유 서방성미립구 및 이의 제조 방법
US8334239B2 (en) 2007-07-10 2012-12-18 The Board Of Regents Of The University Of Texas System High affinity VEGF-receptor antagonists
CA2704056A1 (en) 2007-10-29 2009-05-07 University Of Massachusetts Encapsulated nanoparticles for nucleic acid delivery
KR101045130B1 (ko) 2008-01-09 2011-06-30 경북대학교 산학협력단 태양광을 흡수하여 전기에너지로 전환하는 화합물 및 이의제조 방법
US20120295838A1 (en) 2008-02-08 2012-11-22 Barron Annelise E Selective poly-substituted glycine antibiotics and related compositions
EP2252576A4 (en) 2008-02-08 2012-02-29 Univ Northwestern SELECTIVE POLY-N-SUBSTITUTED GLYCINANTIBIOTICS
WO2009140039A2 (en) 2008-04-23 2009-11-19 The Arizona Board Of Regents Acting For And On Behalf Of Arizona State University Synthetic antibodies
DE102008022712A1 (de) 2008-05-07 2009-11-12 Henkel Ag & Co. Kgaa Haarreinigungsmittel mit Frucht- und/oder Gemüsesaft
US20090318667A1 (en) 2008-05-16 2009-12-24 Kent Kirshenbaum Peptoid compositions and methods of using the same
US20100069308A1 (en) 2008-06-06 2010-03-18 Chorny Iiya Surfaces containing antibacterial polymers
WO2009158315A1 (en) 2008-06-25 2009-12-30 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
EP2309850A4 (en) * 2008-07-31 2013-06-05 Univ Northwestern SURFACE-IMMOBILIZED ANTIMICROBIAL PEPTOIDES
WO2010017412A1 (en) 2008-08-06 2010-02-11 The Regents Of The University Of California Novel biomimetic peptoid polymers
DE102008038137A1 (de) 2008-08-18 2010-02-25 Henkel Ag & Co. Kgaa Sulfatfreies mildes Tensidsystem zur Haut- und Haarreinigung
EP2326178A4 (en) 2008-08-21 2012-10-24 Glaxosmithkline Llc INHIBITORS OF PROLYL-HYDROXYLASE
US20110144167A1 (en) 2008-08-25 2011-06-16 Smithkline Beecham Corporation Prolyl Hydroxylase Inhibitors
AU2009285817B2 (en) 2008-08-28 2014-03-27 University Of Utah Research Foundation Labeled peptides and methods of use thereof for improved oxidation and mapping of disulfide bridges
US8940331B2 (en) 2008-11-22 2015-01-27 The Board Of Trustees Of The Leland Stanford Junior University Hydrogels, methods of making hydrogels, methods of using hydrogels, and methods of isolating, trapping, attracting, and/or killing cancer cells
KR20110096553A (ko) 2008-11-28 2011-08-30 아보트 러보러터리즈 안정한 항체 조성물 및 이의 안정화 방법
CN102438445B (zh) 2009-02-23 2014-12-10 细胞与组织系统股份有限公司 组织的无冰低温贮藏法
WO2010098843A2 (en) 2009-02-24 2010-09-02 New York University Peptoid oligomers, pharmaceutical compositions and methods of using the same
US20120065123A1 (en) 2009-03-24 2012-03-15 Johnston Stephen A Synthetic Antibodies
EP2427476B1 (en) 2009-05-07 2018-08-08 Polyphor Ag Beta-hairpin peptidomimetics having cxcr4 antagonizing activity
RU2627065C2 (ru) 2009-05-08 2017-08-03 Текфилдз Байокем Ко., Лтд. Пролекарственные композиции с высокой степенью проникновения на основе пептидов и родственных пептидам соединений
WO2010135277A2 (en) 2009-05-18 2010-11-25 Brown University Cyclic-glur6 analogs, methods of treatment and use
EP2435827A1 (en) 2009-05-29 2012-04-04 The Board of Regents of The University of Texas System Peptoid ligands for isolation and treatment of autoimmune t-cells
MX2011012933A (es) 2009-06-02 2012-03-07 Univ Texas Identificacion de moleculas pequeñas reconocidas por los anticuerpos en sujetos con enfermedades neurodegerativas.
US20100311036A1 (en) * 2009-06-09 2010-12-09 University Of South Carolina Methods for Augmentation of Cell Cryopreservation
US8716242B2 (en) 2009-12-04 2014-05-06 Polyphor Ag β-hairpin peptidomimetics
GB201001688D0 (en) 2010-02-02 2010-03-17 Novacta Biosystems Ltd Compounds
WO2011115687A2 (en) 2010-03-19 2011-09-22 Northwestern University Alkylated sp-b peptoid compounds and related lung surfactant compositions
US8461300B2 (en) 2010-03-22 2013-06-11 Sandia Corporation Materials and methods for stabilizing nanoparticles in salt solutions
WO2011123179A2 (en) 2010-04-01 2011-10-06 Northwestern University Alkylated sp-c peptoid compounds and related surfactant compositions
EP2561072A4 (en) 2010-04-20 2016-04-06 Univ Florida NANOZYME, METHOD FOR THE PRODUCTION OF NANOCYMENTS AND METHOD FOR THE USE OF NANOCYMENTS
US8952127B2 (en) * 2010-06-04 2015-02-10 The Regents Of The University Of California Peptoids useful for catalyzing the mineralization of calcium carbonate
US9364449B2 (en) 2010-06-09 2016-06-14 New York University Peptoid and synthetic oligomers, pharmaceutical compositions and methods of using same
WO2012085586A1 (en) 2010-12-23 2012-06-28 Shire, Llc Mexiletine prodrugs
RU2013130324A (ru) 2011-01-10 2015-02-20 ОПКО Фармасьютикалз, ЛЛС Суррогаты антигенов при аутоиммунных заболеваниях
AU2012230880B2 (en) 2011-03-24 2017-04-13 Opko Pharmaceuticals, Llc Biomarker discovery in complex biological fluid using bead or particle based libraries and diagnostic kits and therapeutics
JP5959116B2 (ja) 2011-06-07 2016-08-02 Eaファーマ株式会社 ヘテロ環カルボン酸エステル誘導体
WO2013043669A1 (en) 2011-09-21 2013-03-28 The Board Of Regents Of The University Of Texas System Peptoid compositions for the treatment of alzheimer's disease and polyglutamine expansion disorder
DE102012200907A1 (de) 2012-01-23 2013-07-25 Evonik Industries Ag Verfahren und Absorptionsmedium zur Absorption von CO2 aus einer Gasmischung
BR112014022195A2 (pt) * 2012-03-09 2020-05-12 Vestaron Corporation Produção de peptídeo tóxico, expressão de peptídeo em plantas e combinações de peptídeos ricos em cisteína
WO2013158600A1 (en) 2012-04-16 2013-10-24 New York University Multivalent peptoid oligomers, pharmaceutical compositions and methods of using same
EP2887804B1 (en) 2012-05-22 2021-01-27 Trustees of Dartmouth College Cycloalkanyl[b]indoles useful as glp-1 modulators
US10314816B2 (en) 2012-06-08 2019-06-11 Wisconsin Alumni Research Foundation Antimicrobial compounds, compositions and methods of use thereof
DE102012013137A1 (de) 2012-07-03 2014-01-09 Häffner Gmbh & Co. Holding Kg Demarkierungsmittel
US20140100354A1 (en) 2012-10-04 2014-04-10 New York University Peptoid compositions and methods of using the same
WO2014057484A1 (en) * 2012-10-09 2014-04-17 Ramot At Tel-Aviv University Ltd. Peptides for the treatment of neurodegenerative diseases
DE102012221987A1 (de) 2012-11-30 2014-06-05 Henkel Ag & Co. Kgaa Farbglanzmittel mit speziellen kationischen Farbstoffen, Tensiden und Polymeren
US20140256638A1 (en) * 2013-02-14 2014-09-11 The Regents Of The University Of California Peptoid neutralizing agents
US9938321B2 (en) 2013-03-13 2018-04-10 New York University Cyclic peptoid oligomers, pharmaceutical compositions and methods of using the same
TR201911139T4 (tr) 2013-03-15 2019-08-21 Zymeworks Inc Sitotoksik ve anti-mitotik bileşikler ve bunları kullanmanın yöntemleri.
US9764953B2 (en) 2013-03-20 2017-09-19 The Regents Of The University Of California Peptoids useful for the mineralization of apatite
US20160045617A1 (en) 2013-04-10 2016-02-18 Justin C. Lee Treatment of proximal spinal muscular atrophy
US9458449B2 (en) 2013-05-20 2016-10-04 New York University Hybrid polymers, pharmaceutical compositions and methods of synthesizing the same
CA2912642A1 (en) 2013-05-31 2014-12-04 Stefano Menegatti Peptoid affinity ligands for the purification of antibodies or antibody fragments
US10065988B2 (en) 2013-05-31 2018-09-04 Stefano Menegatti Peptoid affinity ligands
EP3033325B1 (en) 2013-07-23 2019-12-04 Arbutus Biopharma Corporation Compositions and methods for delivering messenger rna
HK1209324A1 (en) 2013-08-14 2016-04-01 佛罗里达大学研究基金会公司 Nanozymes, methods of making nanozymes, and methods of using nanozymes
US20150056142A1 (en) 2013-08-20 2015-02-26 The Board Of Trustees Of The Leland Stanford Junior University Near-infrared-ii fluorescent agents, methods of making near-infrared-ii fluorescent agents, and methods of using water-soluble nir-ii fluorescent agents
GB201317207D0 (en) 2013-09-27 2013-11-13 Univ Glasgow Materials and methods for modulating disc1 turnover
US20160251387A1 (en) 2013-10-10 2016-09-01 Merck Patent Gmbh Synthesis of 1-alkyl-2-amino-imidazol-5-carboxylic acid ester via calpha-substituted n-alkyl-glycine ester derivatives
SMT202200393T1 (it) 2013-12-27 2022-11-18 Spexis Ag Peptidomimetici beta-forcina come elastasi inibitori selettivi
CN106102874A (zh) 2014-03-19 2016-11-09 E.W.-海德鲁费利克处理有限公司 过滤器
US10197575B2 (en) 2014-03-31 2019-02-05 H. Lee Moffitt Cancer Center And Research Institute, Inc. Stabilized peptoid-peptide hybrids and uses thereof
US9969773B2 (en) 2014-04-16 2018-05-15 New York University Polymers, pharmaceutical compositions and methods of synthesizing the same
GB2530479A (en) 2014-08-06 2016-03-30 Hilmar Meek Warenius Peptides useful for treating cancer
WO2016059609A1 (en) 2014-10-17 2016-04-21 Dr. Reddy' S Laboratories Limited Acylation process for preparation of liraglutide
MX391259B (es) 2015-10-14 2025-03-21 X Therma Inc Composiciones y métodos para reducir la formación de cristales de hielo.
WO2018191371A1 (en) * 2017-04-12 2018-10-18 X-Therma, Inc. Novel supercooling methods for preservation of biological samples
EP3609906B1 (en) * 2017-04-12 2024-03-20 X-Therma, Inc. Novel peptoid polymers and methods of use
EP3823630A4 (en) * 2018-07-19 2022-04-20 The Regents Of The University Of California PEPTIDES FOR THE ACTIVATION OF CELLULAR SIGNALING IN OSTEOPROGENITOR CELLS
CN111789099B (zh) * 2019-04-09 2022-09-06 北京大学第三医院 一种含肽类化合物的冷冻保存液在卵母细胞或胚胎冻存中的应用
US20210106506A1 (en) * 2019-10-11 2021-04-15 Elc Management Llc Methods for cosmetic skin remodeling

Also Published As

Publication number Publication date
KR102686073B1 (ko) 2024-07-17
ES2958531T3 (es) 2024-02-09
US11510407B2 (en) 2022-11-29
SG11201802777XA (en) 2018-05-30
WO2017066454A2 (en) 2017-04-20
JP2022031718A (ja) 2022-02-22
KR20180084782A (ko) 2018-07-25
EP3370518B1 (en) 2023-08-23
CN108347916B (zh) 2022-02-08
JP7011830B2 (ja) 2022-01-27
US20210100238A1 (en) 2021-04-08
US10694739B2 (en) 2020-06-30
US20170295777A1 (en) 2017-10-19
HK1258922A1 (zh) 2019-11-22
US9986733B2 (en) 2018-06-05
AU2016338410A1 (en) 2018-05-10
WO2017066454A3 (en) 2017-06-15
CN108347916A (zh) 2018-07-31
US20190069537A1 (en) 2019-03-07
IL258648A (en) 2018-06-28
EP3370518A2 (en) 2018-09-12
EP3370518A4 (en) 2019-10-30
CA3001065A1 (en) 2017-04-20
US20250287937A1 (en) 2025-09-18
US12137682B2 (en) 2024-11-12
US20230276788A1 (en) 2023-09-07
AU2016338410B2 (en) 2021-07-15
MX391259B (es) 2025-03-21
JP2018538359A (ja) 2018-12-27

Similar Documents

Publication Publication Date Title
MX2018004518A (es) Composiciones y metodos para reducir la formacion de cristales de hielo.
EP3564356A4 (en) SOLUTION FOR CRYOPRESERVATION, CRYOGENIZATION PRODUCT, AND METHOD FOR CRYOPRESERVATION OF ANIMAL CELLS OR ANIMAL TISSUES
EP4279041A3 (en) Compositions and treatment systems for improved cooling of lipid-rich tissue
MX2022015631A (es) Anticuerpos anti-cd40 humanizados y usos de los mismos.
UY37563A (es) Aislados de bacillus y usos de los mismos
MX352745B (es) Soluciones estabilizadas de acido hipohaloso.
UY37564A (es) Aislados de lysinibacillus y usos de los mismos
CU20170087A7 (es) Formas cristalinas de 5-(4-ciclopropil-1 h-imidazol-1-il)-n-(6-(4-isopropil-4h-1 , 2, 4- triazol-3-il)piridin-2-il)-2-fluoro-4-metilbenzamida
CL2017000562A1 (es) Extracto concentrado de algae, su método de producción y uso del mismo en la agricultura
CY1121762T1 (el) Νεα μεθοδος κατεργασιας φυτικων προϊοντων πριν ή μετα τη συγκομιδη με το φωσφονικο οξυ και ενα αιθεριο ελαιο
CL2017002694A1 (es) Métodos para mejora hidráulica de cultivos
CR20160224A (es) Composición herbicida que comprende inhibidores ACC
MX2016001238A (es) Formulacion de una composicion sanguinea rica en plaquetas y/o factores de crecimiento, con proteinas gelificadas, y metodo de preparacion de la misma.
MX2017008823A (es) Metodos para aislamiento de plaquetas.
MY165444A (en) Thawing vessel for biological products
ECSP17038455A (es) Combinaciones de compuestos activos
ECSP17038476A (es) Combinaciones de compuestos activos
CL2019002340A1 (es) Composiciones y métodos para promover el crecimiento del cabello con inhibidores de mpc1.
ECSP17038441A (es) Combinaciones de compuestos activos
UY37047A (es) Tratamiento in situ de semillas en el surco
MX2020005794A (es) Metodos y composiciones para evitar la lesion por isquemia-reperfusion en organos.
MX2017000231A (es) Ajuste del ph para mejorar la recuperacion por descongelamiento de bancos de celulas.
ECSP17015154A (es) Métodos para mejorar el rendimiento miocárdico en pacientes con cirugía de fontan que utilizan composiciones de udenafilo
MX374241B (es) Formulación de triamida fosfórica o tiofosfórica altamente concentrada.
AR076125A1 (es) Metodos para retardar la maduracion de cultivos